Product Name:
PRP4K-pY849
Product Number:
ab-pk786
Target Full Name: Protein-serine kinase PRP4 homologue
Target Alias: CBP143; KIAA0536; Kinase PRP4; PR4H; Pre-mRNA protein kinase; PRPF4B; PRP4 homolog; PRP4 kinase; PRPK; PR4H; KIAA0536; dJ1013A10_1; PRP4H; PRP4K; ENSG00000112739
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK786
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: Y849
Protein UniProt: Q13523
Protein SigNET: Q13523
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human PRP4K (PRP4, PRPF4B) sequence peptide Cat. No.: PE-04ADK99
Antibody Immunogen Sequence: ITP(pY)LVS(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues I846 to S852; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Production Method: Corresponds to amino acid residues I846 to S852; In protein kinase catalytic domain activation T-loop between subdomains VII and VIII.
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 1 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 95-100, 140 kDa.
Antibody Specificity: Very low
Related Product 1: PRP4K-pY849 blocking peptide
Scientific Background: PRP4K (PRPF4B, PRP4) is a protein-serine/threonine kinase of the CMGC group and DYRK family. It is known to regulate pre-mRNA splicing. Identified substrates for PRP4K include splicing factors SF2, PRPF6, and PRPF31 as well as the KLF13 and Elk1 transcription factors. The enzymatic activity of PRP4K is required for viability of pancreatic, colon and large B-cell lymphoma cancer cell lines (PubMed: 24003220). Inhibition of PRP4K activity by shRNAs was shown to resensitize chemoresistant human ovarian and breast cancer to paclitaxel treatment.
